• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Boehringer Ingelheim, Gubra to validate new Peptides for obesity

cafead

Administrator
Staff member
  • cafead   Mar 02, 2021 at 10:52: AM
via Boehringer Ingelheim has entered into a new research and licensing agreement with biotech company Gubra to identify and validate innovative peptides to treat obesity.

article source
 

<